Latest Distributions News

Downer EDI Limited has announced a fully franked ordinary dividend of AUD 0.141 per share for the six months ending June 2025, with payments scheduled for early October.

Whitehaven Coal Limited has announced a fully franked ordinary dividend of AUD 0.06 per share for the six months ending June 2025, signaling steady returns for shareholders.

Qube Holdings Limited has announced a fully franked ordinary dividend of AUD 0.057 per share for the six months ending June 2025, signaling steady shareholder returns amid a stable operational period.

Pengana International Equities Limited (ASX, PIA) proposes a strategic portfolio enhancement by adding global private credit exposure, aiming to significantly lift fully franked dividends and diversify income streams.

Ridley Corporation reported solid FY25 results with EBITDA up 8.6% to $97.8 million and NPAT rising 8.7% to $43.3 million, underpinned by strategic acquisitions and disciplined capital management.

Redox Limited reported a 9.4% increase in FY25 revenue to $1.244 billion driven by volume growth and strategic acquisitions, while profits declined amid inflationary pressures. The company declared a final dividend of 6.5 cents per share and maintains zero net debt.

Ridley Corporation Limited reported a solid FY25 with revenue up 3.1% to $1.3 billion and net profit after tax rising 8.7% to $43.3 million. The company declared a fully franked final dividend of 5.00 cents per share, signaling confidence in its diversified growth strategy.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Pengana International Equities reported a solid $33.8 million profit for FY2025 and unveiled a strategic plan to diversify into global private credit, aiming to increase dividends by over half and shift to monthly payments.

Charter Hall Group delivered robust full-year 2025 results, marked by operating earnings growth and a strengthened funds management portfolio. The group projects continued momentum into FY26 with increased earnings and distribution guidance.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

Charter Hall Group reported a robust FY25 with a 7.3% rise in operating earnings per security and a surge in funds under management to $84.3 billion. The group’s strategic equity inflows and development pipeline expansion signal strong momentum heading into FY26.